Neuphoria Therapeutics Inc. (NEUP): Entry into a Material Definitive Agreement

Neuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029891401ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 23, 2026, BY AND AMONG SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, INC. AND NEUPHORIA THERAPEUTICS INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, IN

Event · M&A · definitive agreement
Role
target
Counterparty
Scancell Holdings plc
Consideration
stock
Deal value
$89 million
Expected close
late Q4 2026
Also in this documentOffering · $39.1MDebt financing · $25M

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Jul 23, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NEUP
Neutral
medium confidence
Mentioned
$NEUP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NEUPNeutralMed
01

Why it matters

For NEUP, the key market impact is a shift from standalone fundamentals to deal-probability and terms. The excerpt confirms the merger framework but not the economics or closing conditions.

02

Market read

This is a primary-source disclosure of a merger agreement, which can immediately change trading behavior toward deal-arbitrage and closing-probability expectations.

03

What to watch

Traders should focus on the missing specifics: merger consideration, CVR terms, termination fees, regulatory approvals, and any financing contingencies, since these drive deal spread behavior.

Relevance 6/10Novelty 7/10Timing: newly filed 8-K on July 23, 2026, for a pending merger agreement

Background

The SEC 8-K reports Item 1.01, entry into a material definitive agreement, and includes an Agreement and Plan of Merger dated July 23, 2026.

Company-level read

Ticker impact

$NEUPNeutralMedium confidence
Context

Neuphoria Therapeutics entered a material definitive merger agreement, making NEUP the target party in the disclosed transaction.

Expected impact

Near-term trading likely reflects deal-arbitrage dynamics and probability-weighted expectations for closing; direction depends on whether terms are viewed as favorable versus market expectations.

Evidence & confidence

The filing confirms a material definitive agreement and merger structure, but the provided excerpt does not include key deal economics (price, consideration mix, conditions) needed for a precise directional call.

Market effects

Could modestly affect sentiment around small-cap biotech M&A appetite, but no sector-wide regulatory or clinical catalyst is disclosed here.

Limited regional spillover expected since this is a company-specific merger filing.

Low global relevance beyond biotech M&A positioning; no cross-border regulatory action details are included in the excerpt.

Counterpoint

If deal conditions are stringent or financing is uncertain, the stock can trade below offer value despite the agreement headline.

Key entities

  • Neuphoria Therapeutics Inc.

    Target company that entered a material definitive merger agreement, disclosed via SEC Form 8-K.

  • Scancell Holdings plc

    Parent party to the merger agreement (acquirer side), referenced as the parent in the plan of merger.

  • Scancell Merger Sub, Inc.

    Merger subsidiary referenced as the merger sub in the agreement.

Related articles

$NEUPMedAI 8/10

Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing

Scancell Holdings plc (SCLP.L) and Neuphoria Therapeutics Inc. (NEUP) agreed to an all-share merger, with Scancell shareholders owning 85.5% and Neuphoria shareholders 14.5%. The deal includes up to $89m financing via equity and debt, including BlackRock-managed debt. Proceeds will fund iSCIB1+ Phase 3 milestones, with a primary readout in H2 2028. Shareholder approval is pending.

$NEUPHighAI 9/10

Merger and Financing

Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) announced an all-share merger where Scancell will acquire Neuphoria. The combined company plans to list on Nasdaq under symbol SCLT. Scancell expects up to $89m financing via equity and debt, including $39.1m private placement, about $15m UK equity, and up to $25m debt. Shareholder approval is required.

$FFAIMed

Faraday Future (FFAI) Q3 2026 Earnings Call Transcript

Faraday Future (FFAI) reported Q3 2026 earnings, highlighting the October 23 acquisition of its robotics business by FFEAI Robotics Ecosystem (FFR) for $200M. FFAI now operates as an AI investment holding company, with FFR as a subsidiary. FFR, led by YT Jia, focuses on robotics, selling 351 devices in October. FFAI retains 66% ownership of FFR, which is included in consolidated financial statements.

$MARAMed

MARA Raises $185 Million to Fund Long Ridge Power Plant Deal

MARA raised $185 million via 8.750% senior secured notes due 2032 to fund its acquisition of Long Ridge Energy, a 505 MW gas plant. Proceeds will also repay part of Long Ridge's debt and cover fees. The offering is expected to close on November 27, 2026, alongside the acquisition. MARA has reduced its total debt by $1.4 billion in 2026 and authorized a $500 million share repurchase program.

$COSTHigh

The Best Recession-Proof Consumer Stock to Buy With $1,000 Before 2027

Costco (COST) reported Q4 2026 sales growth of 11.2%, with comparable sales up 9.4%. The company announced a $30 special dividend, its highest ever, boosting its stock by 5%. Costco's unique model, offering low prices and membership fees, drives loyalty and sales, especially during economic downturns. Gas stations and e-commerce are key growth drivers, with digitally-enabled sales up 20% YoY.